Published July 6, 2015 | Version Supplemental Material + Accepted Version
Journal Article Open

An Efficient Protocol for the Palladium-Catalyzed Asymmetric Decarboxylative Allylic Alkylation Using Low Palladium Concentrations and a Palladium(II) Precatalyst

Abstract

Enantioselective catalytic allylic alkylation for the synthesis of 2-alkyl-2-allylcycloalkanones and 3,3-disubstituted pyrrolidinones, piperidinones and piperazinones has been previously reported by our laboratory. The efficient construction of chiral all-carbon quaternary centers by allylic alkylation was previously achieved with a catalyst derived in situ from zero-valent palladium sources and chiral phosphinooxazoline (PHOX) ligands. We now report an improved reaction protocol with broad applicability among different substrate classes in industry-compatible reaction media using loadings of palladium(II) acetate as low as 0.075 mol% and the readily available chiral PHOX ligands. The novel and highly efficient procedure enables facile scale-up of the reaction in an economical and sustainable fashion.

Additional Information

© 2015 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim. Received: March 13, 2015; Revised: May 21, 2015; Published online: July 14, 2015. We wish to thank the NIH-NIGMS (R01M080269), Amgen, AbbVie, Boehringer Ingelheim, and Caltech for financial support. This material is based upon work supported by the German National Academy of Sciences Leopoldina under Grant No. LPDS 2011-12 (fellowship to A.N.M.). D.C.D. is grateful for financial support from the National Science Foundation (Predoctoral Research Fellowship, No. DGE-1144469). We also wish to thank the National Cancer Institute of the National Institutes of Health under Award Number F31A174359 (fellowship to R.A.C.), and the Swiss National Science Foundation (SNSF, fellowship for M.L.). Y.N. thanks Toray Industries, Inc. for a postdoctoral fellowship. Dr. Scott Virgil is acknowledged for assistance with instrumentation. Dr. John A. Enquist and Dr. Nathaniel H. Sherden are acknowledged for preliminary experimental work related to these results. Dr. Douglas C. Behenna is acknowledged for insightful discussions.

Attached Files

Accepted Version - nihms768886.pdf

Supplemental Material - adsc_201500253_sm_miscellaneous_information.pdf

Files

adsc_201500253_sm_miscellaneous_information.pdf

Files (4.0 MB)

Name Size
md5:0f885c9cbc39e80c657e9710292550ba
3.5 MB Preview Download
md5:08ca14d6712c3d48c05403a6ef15cf65
552.4 kB Preview Download

Additional details

Identifiers

PMCID
PMC4811629
Eprint ID
58951
DOI
10.1002/adsc.201500253
Resolver ID
CaltechAUTHORS:20150720-144300390

Related works

Describes
10.1002/adsc.201500253 (DOI)

Funding

NIH
R01M080269
Amgen
AbbVie
Boehringer Ingelheim
Caltech
National Academy of Sciences Leopoldina
LPDS 2011-12
NSF Graduate Research Fellowship
DGE-1144469
NIH Predoctoral Fellowship
F31A174359
Swiss National Science Foundation (SNSF)
Toray Industries, Inc.

Dates

Created
2015-07-21
Created from EPrint's datestamp field
Updated
2022-05-26
Created from EPrint's last_modified field